ArticleJournal of Cancer2018
The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.
Article in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.International journal of colorectal disease · 2021Pooled it
- Interactions Between Circulating Tumor Cells and the Immune System in Colorectal Cancer: Friends or Foes?Cancers · 2026Review
- Immune architecture of colorectal cancer brain metastases: spatial TAM heterogeneity and PD-L1 dynamics.Frontiers in immunology · 2026Article
- A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis.Current therapeutic research, clinical and experimental · 2024Review
- Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer.Scientific reports · 2022Article
- An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.BMC cancer · 2022Article
- Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma.Frontiers in immunology · 2022Article
- PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers.Journal of personalized medicine · 2021Article
- PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.PloS one · 2021Article
- IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.OncoTargets and therapy · 2021Article
- Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.Frontiers in molecular neuroscience · 2021Article
- Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.